15.90

3.65% 0.56

Bausch Lomb Corp (BLCO)

Overview News Price History Option Chain Financials Discussions Forecast

Bausch Lomb Corp stock is traded at $15.90, with a volume of 742.04K. It is up +3.65% in the last 24 hours and up +0.00% over the past month. Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Previous Close:

$15.34

Open:

$15.32

24h Volume:

742.04K

Relative Volume:

1.73

Market Cap:

$5.67B

Revenue:

$5.10B

Net Income/Loss:

$-352.00M

P/E Ratio:

-15.61

EPS:

-1.0189

Net Cash Flow:

$-66.14M

1W Performance:

+0.76%

1M Performance:

+0.00%

6M Performance:

+6.43%

1Y Performance:

+37.54%

1-Day Range:

$15.32

$15.91

1-Week Range:

$15.26

$16.39

52-Week Range:

$10.83

$18.91

Bausch Lomb Corp Stock (BLCO) Company Profile

Name

Bausch Lomb Corp

Sector

Healthcare (1105)

Industry

Medical Instruments & Supplies (57)

Phone

908-541-5456

Address

520 APPLEWOOD CRESCENT, VAUGHAN

Employee

13,000

Twitter

Next Earnings Date

2026-04-29

Latest SEC Filings

BLCO's Discussions on Twitter

Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLCO Bausch Lomb Corp	15.90	5.60B	5.10B	-352.00M	-66.14M	-1.0189
ISRG Intuitive Surgical Inc	457.61	165.27B	10.58B	3.00B	2.83B	8.2437
BDX Becton Dickinson Co	149.04	42.53B	21.92B	1.76B	2.63B	6.1223
MDLN Medline Inc	44.47	37.41B	28.43B	1.16B	1.26B	1.4457
ALC Alcon Inc	74.87	36.75B	10.40B	980.00M	1.61B	1.9749
RMD Resmed Inc	213.81	31.63B	5.40B	1.49B	1.78B	10.12

Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Dec-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-01-25	Initiated	Goldman	Neutral
May-02-25	Reiterated	H.C. Wainwright	Buy
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform
Jul-10-24	Initiated	Raymond James	Outperform
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-12-23	Initiated	Stifel	Hold
Oct-03-23	Resumed	Evercore ISI	Outperform
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight
Sep-12-22	Initiated	H.C. Wainwright	Buy
Jul-26-22	Initiated	RBC Capital Mkts	Outperform
Jun-24-22	Initiated	Evercore ISI	Outperform
Jun-06-22	Initiated	Citigroup	Buy
May-31-22	Initiated	Deutsche Bank	Hold
May-31-22	Initiated	Goldman	Neutral
May-31-22	Initiated	Guggenheim	Buy
May-31-22	Initiated	JP Morgan	Neutral
May-31-22	Initiated	Jefferies	Buy
May-31-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Initiated	Wells Fargo	Overweight
May-11-22	Initiated	Cowen	Outperform

View All

Bausch Lomb Corp Stock (BLCO) Latest News

Apr 30, 2026

Bausch & Lomb Corp Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights - Minichart

Apr 30, 2026

BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating - 富途牛牛

Apr 30, 2026

Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16 - 富途牛牛

Apr 30, 2026

A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $21 - 富途牛牛

Apr 30, 2026

From dry eye to glaucoma, 40+ Bausch + Lomb studies head to Denver - Stock Titan

Apr 30, 2026

BofA raises Bausch & Lomb stock price target on earnings beat - Investing.com Australia

Apr 30, 2026